Inolife (BTGN) 10-Q 19 Nov 14 2015 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Sep. 30, 2014	Nov. 13, 2014
Document And Entity Information	'	'
Entity Registrant Name	'INOLIFE TECHNOLOGIES, INC.	'
Entity Central Index Key	'0001297965	'
Document Type	'10-Q	'
Document Period End Date	30-Sep-14	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--03-31	'
Is Entity a Well-known Seasoned Issuer?	'No	'
Is Entity a Voluntary Filer?	'No	'
Is Entity's Reporting Status Current?	'Yes	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	567,530,492
Document Fiscal Period Focus	'Q2	'
Document Fiscal Year Focus	'2015	'

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 30, 2014	Mar. 31, 2014
Current Assets:	'	'
Cash and cash equivalents	$103	$3
Prepaid Expenses	'	'
Total Current Assets	103	3
TOTAL ASSETS	103	3
Current Liabilities:	'	'
Accounts payable	850,575	787,874
Accrued management fees, related party	1,024,424	684,788
Accrued consulting fees	77,700	52,500
Accrued employer taxes	107,663	280,149
Accrued interest	209,294	190,365
Convertible notes payable	550,829	550,829
Derivative Liability	228,000	228,000
Notes payable - related party	78,958	78,959
Total Current Liabilities	3,127,443	2,853,464
TOTAL LIABILITIES	3,127,443	2,853,464
Stockholders' Deficit	'	'
Preferred stock: 100,000,000 authorized; $0.00001 par value 132,774 and 213,322 issued and outstanding, respectively	52	2
Preferred Stock - Series C, par value $0.01 per share, 572 and 572 issued and outstanding, respectively	6	6
Common stock: 5,000,000,000 authorized; $0.00001 par value 519,280,492 and 40,040,492 issued and outstanding, respectively	2,725	1,000
Additional paid in capital	7,669,299	7,330,423
Accumulated deficit	-10,799,422	-10,184,892
Total Shareholders' Deficit	-3,127,340	-2,853,461
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$103	$3

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Sep. 30, 2014	Mar. 31, 2014
SHAREHOLDERS' EQUITY (DEFICIT)	'	'
Preferred stock, par value	$0.00	$0.00
Preferred stock, Authorized	100,000,000	100,000,000
Preferred stock, Issued	132,774	213,322
Preferred stock, outstanding	132,774	213,322
Preferred stock series C, par value	$0.01	$0.01
Preferred stock series C, Issued	572	572
Preferred stock series C, outstanding	572	572
Common stock, par value	$0.00	$0.00
Common stock, Authorized	5,000,000,000	5,000,000,000
Common stock, Issued	519,280,492	40,040,492
Common stock, outstanding	519,280,492	40,040,492

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Consolidated Statements Of Operations	'	'	'	'
Revenues	'	'	'	'
Operating Expenses	'	'	'	'
Professional fees	22,900	24,095	222,150	1,132,902
Management expenses	77,500	146,000	361,300	1,084,000
Selling, general and administrative expense	5,928	8,282	12,150	37,751
Total operating expenses	106,328	178,377	595,600	2,254,653
Net loss from operations	-106,328	-178,377	-595,600	-2,254,653
Other income (expenses)	'	'	'	'
Interest expense	-9,465	-35,902	-18,929	-58,827
Gain on debt forgiveness	'	'	'	11,757
Other Income	'	14,211	'	14,211
Change in fair value of derivative	'	'	'	137,344
Total other income (expenses)	-9,465	-21,691	-18,929	104,485
Loss before provision for taxes	-115,793	-200,068	-614,529	-2,150,168
Provision for income taxes	'	'	'	'
Net loss	($115,793)	($200,068)	($614,529)	($2,150,168)
Basic and diluted loss per share	$0	$0	$0	($0.01)
Weighted average number of shares outstanding	488,575,208	158,367,451	464,700,474	165,008,930

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'
Net Loss	($614,529)	($2,150,168)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:	'	'
Change in fair value of derivative	'	-137,344
Gain on debt forgiveness	'	-11,757
Common stock issued in exchange for services	310,548	1,845,922
Beneficial conversion feature related to issuance of convertible debentures	'	20,000
Changes in assets and liabilities:	'	'
(Increase) Decrease in prepaid expense	'	53,750
Increase (Decrease) in accounts payable	92,803	19,425
Increase(Decrease) in accrued liabilities	-147,286	36,270
Increase(Decrease) in Management fess	339,636	292,000
Increase(Decrease) in note payable to related parties	'	14,798
Increase(Decrease) in accrued interest	18,929	22,104
Net Cash Used in Operating Activities	100	5,000
CASH FLOWS PROVIDED BY (USED FOR) INVESTING ACTIVITIES :	'	'
Net Cash Used in Investing Activities	'	'
CASH FLOWS PROVIDED BY (USED FOR) FINANCING ACTIVITIES:	'	'
Net Cash Provided by (Used for) Financing Activities	'	'
NET INCREASE (DECREASE) IN CASH	100	5,000
CASH AT BEGINNING OF PERIOD	3	'
CASH AT END OF PERIOD	103	5,000
SUPPLEMENTAL CASH FLOW INFORMATION:	'	'
Cash Paid for interest	'	'
Cash Paid for taxes	'	'
Common Stock issued for services	310,548	1,845,922
Common Stock issued upon conversion	'	$44,000

THE_COMPANY

THE COMPANY	6 Months Ended
	Sep. 30, 2014
Notes to Financial Statements	'
NOTE 1 - THE COMPANY	'
	HISTORY
	InoLife Technologies, Inc. (the “Company”) was incorporated under the laws of the State of New York on November 12, 1998 as Safe Harbour Health Care Properties, Ltd. During 1999, the Company ceased its operations. The Company remained dormant until 2004, when one of the Company’s shareholders purchased a controlling interest. In February 2004, the Company began its development stage as an internet based marketing company. The Company, as of December 2007 discontinued its internet marketing due to difficulties with service providers and subsequent cancellations by customers.
	In August 2009, Gary Berthold purchased 35,013,540 shares of InoLife Technologies, Inc. representing a majority of the outstanding shares. In connection with the purchase, all of the directors and officers of the Company resigned from their positions, after first appointing Berthold as a director.
	Effective September 17, 2009, the Board of Directors of the Company authorized the execution of a share exchange agreement (the “Share Exchange Agreement”) with InoVet, Ltd., a Delaware corporation (“InoVet”) and the shareholders of InoVet (the “InoVet Shareholders”). In accordance with the terms and provisions of the Share Exchange Agreement, the Company agreed to: (i) acquire all of the issued and outstanding shares of common stock of InoVet from the InoVet Shareholders; and (ii) issue an aggregate of 10,000,000 shares of its restricted common stock to the InoVet Shareholders.
	On July 7, 2011, the Company acquired 100% of the issued and outstanding shares of Stemtide Inc. in exchange for 50,000,000 shares of common stock of the Company, the assumption of certain outstanding liabilities, and contingent residual payments of 10% of the gross profits derived from the sale of Stemtide Inc.’s Age-Reversing Products. The principal asset of Stemtide Inc. that was acquired was the manufacturing and marketing rights to the Stemtide Age-Reversing Products, throughout the United States, licensed from an affiliate of the principal shareholders of InoLife.

SUMMARY_OF_SIGNIFICANT_ACCOUNT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Sep. 30, 2014
Notes to Financial Statements	'
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
	Unaudited Interim Consolidated Financial Statements:
	The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States (“GAAP”) for complete consolidated financial statements. In the opinion of management, all adjustments (consisting only of normal recurring accruals, unless otherwise indicated) considered necessary for a fair presentation of the interim financial data have been included. Operating results for the three and six months ended September 30, 2014 are not necessarily indicative of the results that may be expected for the fiscal year ending March 31, 2015. Events occurring subsequent to September 30, 2014 have been evaluated for potential recognition or disclosure in the unaudited consolidated financial statements for the three and six months ended September 30, 2014.
	The accompanying unaudited consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2014, which were filed with the Securities and Exchange Commission (the “SEC”) on July 15, 2014.
	The condensed consolidated balance sheet at March 31, 2014 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by generally accepted accounting principles in the U.S. for complete financial statements.
	The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
	Management believes that all adjustments necessary for a fair statement of the results of the three and six months ended September 30, 2014 and 2013 have been made.
	Significant Accounting Policies:
	Basis of Presentation:
	The Company prepares its consolidated financial statements on the accrual basis of accounting. All intercompany balances and transactions are eliminated.
	Cash and Cash Equivalents:
	All highly liquid investments with original maturities of three months or less are included in cash and cash equivalents. All deposits are maintained in FDIC insured depository accounts in local financial institutions and balances are insured up to $250,000.
	Earnings Per Share:
	Basic earnings (loss) per share are computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period. Diluted earnings (loss) per share include the effects of any outstanding options, warrants and other potentially dilutive securities. Basic and diluted earnings per share (“EPS”) are based on weighted-average common shares and exclude shares that would have an anti-dilutive effect. The Company did not consider any potential common shares in the computation of diluted EPS as of September 30, 2014 and 2013, due to the loss from operations, as they would have an anti-dilutive effect on EPS.
	Share Based Payments:
	The Company accounts for share based payments using a fair value based method whereby compensation cost is measured at the grant date based on the value of the services received and is recognized over the service period. The Company uses the Black-Scholes pricing model to calculate the fair value of options and warrants issued. In calculating this fair value, there are certain assumptions used such as the expected life of the option, risk-free interest rate, dividend yield, volatility and forfeiture rate. The use of a different estimate for any one of these components could have a material impact on the amount of calculated compensation expense.
	Segment Reporting
	The Company has determined it has only one operating segment as of the periods presented.
	Income Taxes
	The Company accounts for income taxes under ASC 740 Income Taxes. Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. The Company has had significant operating losses and a valuation allowance is recorded for the entire amount of the deferred tax assets, resulting in no deferred tax assets or liabilities recognized as of September 30, 2014 and March 31, 2014.
	The Company accounts for uncertain tax positions according to the provisions of ASC 740. ASC 740 contains a two-step approach for recognizing and measuring uncertain tax positions. Tax positions are evaluated for recognition by determining if the weight of available evidence indicates that it is probable that the position will be sustained on audit, including resolution of related appeals or litigation. Tax benefits are then measured as the largest amount which is more than 50% likely of being realized upon ultimate settlement. The Company considers many factors when evaluating and estimating tax positions and tax benefits, which may require periodic adjustments and which may not accurately anticipate actual outcomes.
	The Company’s open tax periods are 2009 through 2013.
	Reclassification
	Certain reclassifications have been made to prior year amounts to conform to the current period presentation.
	Recently Issued Accounting Pronouncements:
	On June 10, 2014 the FASB issued ASU No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation. The amendments in this ASU remove all incremental financial reporting requirements from U.S. GAAP for development stage entities. The Company has elected to early adopt this guidance, and therefore is no longer presenting the financial statements in accordance with ASU 915, with inception to date disclosures.
	The Company is evaluating how to apply ASU 605, Revenues from Contracts with Customers, before its effective date, however, as the Company does not yet have revenue to recognize, it will not have an impact on current results of operations, financial position or cash flow.

CONVERTIBLE_NOTES_PAYABLE

CONVERTIBLE NOTES PAYABLE	6 Months Ended
	Sep. 30, 2014
Notes to Financial Statements	'
NOTE 3. CONVERTIBLE NOTES PAYABLE	'
	Convertible notes payable consist of the following at September 30, 2014 and March 31, 2014:
		Due Date			Interest				September 30,		March 31,
									2014		2014
	E-Lionheart	2/3/12				8	%			203,960		203,960
	Longside Ventures	various				various				269,269		269,269
	Orchid	5/12/12				0	%			37,600		37,600
	Just Marketing	Demand				10	%			40,000		40,000
										550,829		550,829
	The Company has evaluated their convertible notes for embedded derivative features and has determined that in several of the notes a derivative liability is necessary to recognize. These notes contain a conversion feature which includes a “reset” provision, whereby the conversion rate would be reset should there be future equity sales at a price less than the conversion rate in effect at the time. Therefore, the conversion feature is required to be bifurcated and accounted for under derivative accounting, and remeasured each period end, with any changes in the fair value of the derivative to be recognized in income. During the three and six months ended September 30, 2014 there was no change in fair value of the derivative liability. During the three and six months ended September 30, 2013 there was a reduction in the derivative liability of $137,344 due to the reduction of the related notes principal balances, which was recognized as a separate line item on the accompanying Statement of Operations . The fair value of the derivative liability as of both September 30, 2014 and March 31, 2014, has been determined to be $228,000. Derivative liabilities were valued using a probability based weighted-average Black-Scholes-Merton valuation with the following assumptions:
		30-Sep-14					March 31,
							2014
	Risk-free interest rate		0.02	%				0.03	%
	Expected volatility		100	%				100	%
	Expected life (in years)		0					0
	Expected dividend yield		0	%				0	%
	At September 30, 2014 and March 31, 2014 the accrued interest on all notes is approximately $60,000 and $41,500, respectively.

RELATED_PARTY_TRANSACTIONS

RELATED PARTY TRANSACTIONS	6 Months Ended
	Sep. 30, 2014
Notes to Financial Statements	'
NOTE 4. RELATED PARTY TRANSACTIONS	'
	On June 2, 2014, the Company issued 5,000,000 shares of its Series B Preferred Stock (“PS”) to the CEO, who is also one of the founders and majority shareholders of the Company. The PS is convertible into common stock six months after issuance, at a mathematical calculation, which as of issuance represented a 1 PS to 250,000 common stock conversion ratio. The PS has been recognized as a distribution of capital, which resulted in no impact on additional paid in capital.

COMMON_AND_PREFERRED_STOCK

COMMON AND PREFERRED STOCK	6 Months Ended
	Sep. 30, 2014
Notes to Financial Statements	'
NOTE 5 - COMMON & PREFERRED STOCK	'
	Please see Note 4 for a discussion of Preferred Stock issued to related parties.
	During August 2014 the Company sold 49,000,000 of its common stock for cash consideration of $30,000. The cash proceeds were used to pay down certain accounts payable balances.
	On June 2, 2014 the Company issued 205,000,000 shares of its common stock and 200,000 of its Series B Preferred Stock (“PS”) for services to various directors and officers of the Company, and attorneys. The fair value of the common stock was $307,500, which was determined using the market price of the Company’s common stock on the date of issuance. The PS is convertible into common stock six months after issuance, at a mathematical calculation, which as of issuance represented a 1 PS to 250,000 common stock conversion ratio. Each share of PS shall have ten votes for any vote placed before the shareholders of the Corporation. As the PS is convertible into such a large block of common stock, the Company determined the fair value of the underlying shares issuable upon conversion was not an appropriate valuation method, and did not result in a reasonable compensation expense. The Company determined instead that the relationship of the PS to the common stock demonstrated by the ten to one voting power was a more sound basis for the calculation of the fair value of the PS based on the fair value of the common shares. This resulted in recognition of the PS with a fair value of $3,050.
	The PS was analyzed for any derivative accounting issues which might require bifurcation from the host instrument, and the conversion feature was identified as the only embedded derivative. As the PS is clearly and closely related to the conversion feature, in that both have economic characteristics and risks that are considered those of an equity instrument, the conversion feature does not qualify for bifurcation.

FINANCIAL_CONDITION_AND_GOING_

FINANCIAL CONDITION AND GOING CONCERN	6 Months Ended
	Sep. 30, 2014
Notes to Financial Statements	'
Note 6 - FINANCIAL CONDITION AND GOING CONCERN	'
	The Company has minimal operations and has negative working capital at September 30, 2014. Due to the limited operating history and limited operations, the Company will require additional working capital to survive. The Company is currently working on completing and going live with their website, through which they will market their products. The first products to be marketed will be the Stemtide Anti-Aging Products Line. Management expects revenue on these products to begin being recognized during the first quarter of fiscal 2015. If the funds the Company has are not sufficient, it will also consider bank loans and additional shareholder loans. There are no assurances that the Company will be able to obtain any of these. No assurance can be given that additional financing will be available, or will be available, will be on terms acceptable to the Company. If adequate working capital cannot be generated, the Company may not be able to continue its operations.
	These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments relating to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might be necessary should the Company be able to continue as a going concern.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Sep. 30, 2014
Notes to Financial Statements	'
NOTE 7 - SUBSEQUENT EVENTS	'
	Management has evaluated all activity of the Company through November 19, 2014 (the issue date of the financial statements) and concluded that the following additional subsequent events have occurred that require recognition in the financial statements or disclosure in the notes to financial statements.
	The Company raised $30,000 in cash proceeds through the sale of 48,250,000 shares of their common stock on November 3, 2014.

SUMMARY_OF_SIGNIFICANT_ACCOUNT1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Sep. 30, 2014
Summary Of Significant Accounting Policies Policies	'
Basis of Presentation	'
	The Company prepares its consolidated financial statements on the accrual basis of accounting. All intercompany balances and transactions are eliminated.
Cash and Cash Equivalents	'
	All highly liquid investments with original maturities of three months or less are included in cash and cash equivalents. All deposits are maintained in FDIC insured depository accounts in local financial institutions and balances are insured up to $250,000.
Earnings Per Share	'
	Basic earnings (loss) per share are computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period. Diluted earnings (loss) per share include the effects of any outstanding options, warrants and other potentially dilutive securities. Basic and diluted earnings per share (“EPS”) are based on weighted-average common shares and exclude shares that would have an anti-dilutive effect. The Company did not consider any potential common shares in the computation of diluted EPS as of September 30, 2014 and 2013, due to the loss from operations, as they would have an anti-dilutive effect on EPS.
Share Based Payments	'
	The Company accounts for share based payments using a fair value based method whereby compensation cost is measured at the grant date based on the value of the services received and is recognized over the service period. The Company uses the Black-Scholes pricing model to calculate the fair value of options and warrants issued. In calculating this fair value, there are certain assumptions used such as the expected life of the option, risk-free interest rate, dividend yield, volatility and forfeiture rate. The use of a different estimate for any one of these components could have a material impact on the amount of calculated compensation expense.
Segment Reporting	'
	The Company has determined it has only one operating segment as of the periods presented.
Income Taxes	'
	The Company accounts for income taxes under ASC 740 Income Taxes. Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. The Company has had significant operating losses and a valuation allowance is recorded for the entire amount of the deferred tax assets, resulting in no deferred tax assets or liabilities recognized as of September 30, 2014 and March 31, 2014.
	The Company accounts for uncertain tax positions according to the provisions of ASC 740. ASC 740 contains a two-step approach for recognizing and measuring uncertain tax positions. Tax positions are evaluated for recognition by determining if the weight of available evidence indicates that it is probable that the position will be sustained on audit, including resolution of related appeals or litigation. Tax benefits are then measured as the largest amount which is more than 50% likely of being realized upon ultimate settlement. The Company considers many factors when evaluating and estimating tax positions and tax benefits, which may require periodic adjustments and which may not accurately anticipate actual outcomes.
	The Company’s open tax periods are 2009 through 2013.
Recently Issued Accounting Pronouncements	'
	On June 10, 2014 the FASB issued ASU No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation. The amendments in this ASU remove all incremental financial reporting requirements from U.S. GAAP for development stage entities. The Company has elected to early adopt this guidance, and therefore is no longer presenting the financial statements in accordance with ASU 915, with inception to date disclosures.
	The Company is evaluating how to apply ASU 605, Revenues from Contracts with Customers, before its effective date, however, as the Company does not yet have revenue to recognize, it will not have an impact on current results of operations, financial position or cash flow.

CONVERTIBLE_NOTES_PAYABLE_Tabl

CONVERTIBLE NOTES PAYABLE (Tables)	6 Months Ended
	Sep. 30, 2014
Convertible Notes Payable Tables	'
Convertible notes payable	'
	Convertible notes payable consist of the following at September 30, 2014 and March 31, 2014:
		Due Date			Interest				September 30,		March 31,
									2014		2014
	E-Lionheart	2/3/12				8	%			203,960		203,960
	Longside Ventures	various				various				269,269		269,269
	Orchid	5/12/12				0	%			37,600		37,600
	Just Marketing	Demand				10	%			40,000		40,000
										550,829		550,829
Derivative liabilities	'
	Derivative liabilities were valued using a probability based weighted-average Black-Scholes-Merton valuation with the following assumptions:
		30-Sep-14					March 31,
							2014
	Risk-free interest rate		0.02	%				0.03	%
	Expected volatility		100	%				100	%
	Expected life (in years)		0					0
	Expected dividend yield		0	%				0	%

CONVERTIBLE_NOTES_PAYABLE_Deta

CONVERTIBLE NOTES PAYABLE (Details) (USD $)	6 Months Ended	12 Months Ended
	Sep. 30, 2014	Mar. 31, 2014
Convertible notes payable, Net	$550,829	$550,829
E-Lionheart [Member]	'	'
Due Date	3-Feb-12	3-Feb-12
Interest, Percentage	8.00%	8.00%
Convertible notes payable, Net	203,960	203,960
Longside Ventures [Member]	'	'
Due Date	'various	'various
Interest	'various	'various
Convertible notes payable, Net	269,269	269,269
Orchid [Member]	'	'
Due Date	12-May-12	12-May-12
Interest, Percentage	0.00%	0.00%
Convertible notes payable, Net	37,600	37,600
Just Marketing [Member]	'	'
Due Date	'Demand	'Demand
Interest, Percentage	10.00%	10.00%
Convertible notes payable, Net	$40,000	$40,000

CONVERTIBLE_NOTES_PAYABLE_Deta1

CONVERTIBLE NOTES PAYABLE (Details 1)	6 Months Ended	12 Months Ended
	Sep. 30, 2014	Mar. 31, 2014
Convertible Notes Payable Details 1	'	'
Risk-free interest rate	0.02%	0.03%
Expected volatility	100.00%	100.00%
Expected life (in years)	'0 years	'0 years
Expected dividend yield	0.00%	0.00%

CONVERTIBLE_NOTES_PAYABLE_Deta2

CONVERTIBLE NOTES PAYABLE (Details Narrative) (USD $)	3 Months Ended	6 Months Ended
	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2014	Mar. 31, 2014
Convertible Notes Payable Details Narrative	'	'	'	'
Fair value of the derivative liability	'	'	$228,000	$228,000
Accrued interest	'	'	60,000	41,500
Change in fair value of derivative liability	$137,344	$137,344	'	'